DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Peer Reviewed Medical
  4. Research Highlights/News
  5. 2019 Peer Reviewed Medical Research Program

Peer Reviewed Medical

NEWS RELEASE

Released: November 6, 2018

The Defense Health Program
Department of Defense Peer Reviewed Medical Research Program
Anticipated Funding Opportunities for Fiscal Year 2019 (FY19)

The FY19 Defense Appropriations Act provides $350 million (M) to the Department of Defense Peer Reviewed Medical Research Program (PRMRP) to support medical research projects of clear scientific merit and direct relevance to military health. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The PRMRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY19 PRMRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in November 2018. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.

The vision and mission of the PRMRP is improve the health, care, and well-being of all military Service members, Veterans, and beneficiaries by encouraging, identifying, selecting, and managing medical research projects of clear scientific merit and direct relevance to military health.

Congressionally Directed Topic Areas: All applications submitted to the PRMRP must address at least one of the FY19 PRMRP Congressionally directed topic areas. The FY19 PRMRP Topic Areas are as follows:

  • Acute Lung Injury
  • Antimicrobial Resistance
  • Arthritis
  • Burn Pit Exposure
  • Cardiomyopathy
  • Cerebellar Ataxia
  • Chronic Migraine and Post-Traumatic Headache
  • Congenital Heart Disease
  • Constrictive Bronchiolitis
  • Diabetes
  • Dystonia
  • Eating Disorders
  • Emerging Infectious Diseases
  • Epidermolysis Bullosa
  • Focal Segmental Glomerulosclerosis
  • Frontotemporal Degeneration
  • Guillain-Barr� Syndrome
  • Hemorrhage Control
  • Hepatitis B
  • Hereditary Angioedema
  • Hydrocephalus
  • Immunomonitoring of Intestinal Transplants
  • Inflammatory Bowel Diseases
  • Interstitial Cystitis
  • Lung Injury
  • Metals Toxicology
  • Mitochondrial Disease
  • Musculoskeletal Disorders
  • Myotonic Dystrophy
  • Nanomaterials for Bone Regeneration
  • Nutrition Optimization
  • Pancreatitis
  • Pathogen-Inactivated Blood Products
  • Polycystic Kidney Disease
  • Post-Traumatic Osteoarthritis
  • Pressure Ulcers
  • Pulmonary Fibrosis
  • Resilience Training
  • Respiratory Health
  • Rett Syndrome
  • Rheumatoid Arthritis
  • Scleroderma
  • Sleep Disorders
  • Spinal Muscular Atrophy
  • Tinnitus
  • Tissue Regeneration
  • Tuberculosis
  • Vascular Malformations
  • Women's Heart Disease

The following mechanisms are planned for release:

Award Mechanism Eligibility Key Mechanism Elements Funding
Clinical Trial Award Assistant Professor level or above (or equivalent)
  • Preproposal submission is required; application submission is by invitation only.
  • Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.
  • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
  • Investigational New Drug or Investigational Device Exemption applications, if needed, should be approved by the Food and Drug Administration by the PRMRP application submission deadline.
  • Funding limit not defined; requested funding must be appropriate for the scope of work proposed
  • Maximum period of performance is 4 years
Discovery Award Postdoctoral fellow or clinical fellow (or equivalent) and above
  • Supports the exploration of a highly innovative new concept or untested theory.
  • Not intended to support the logical progression of an already established line of questioning.
  • Clinical trials will not be funded.
  • Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s).
  • Maximum of $200,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 2 years
Focused Program Award Full Professor level or above (or equivalent)
  • Preproposal submission is required; application submission is by invitation only.
  • Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal.
  • Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
  • Projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.
  • Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.
  • Maximum of $7.2 million for direct costs (plus indirect costs)
  • Maximum period of performance is 4 years
Investigator-Initiated Research Award Assistant Professor level or above (or equivalent)
  • Preproposal submission is required; application submission is by invitation only.
  • Supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.
  • Partnering PI Option available.
  • Clinical trials will not be funded.
  • Maximum of $1.2 million for direct costs (plus indirect costs)
  • Maximum of $1.5 million for direct costs (plus indirect costs) for applications including a Partnering PI Option
  • Maximum period of performance is 3 years
Technology/ Therapeutic Development Award Assistant Professor level or above (or equivalent)
  • Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life.
  • Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
  • Clinical trials will not be funded.
  • Preproposal submission is required; application submission is by invitation only.
  • Maximum of $3.0 million for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government's single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage at https://eBRAP.org. For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website (httpcdmrp.health.mil.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Monday, December 16, 2024